Search
+
    SEARCHED FOR:

    CIPLA LTD MD

    Cipla sets sights on first-wave gains from rollout of Keytruda Biosimilar

    Cipla has partnered with Qilu Pharmaceutical to commercialize a biosimilar of Keytruda, which is a major cancer treatment. The patent for this drug is expected to expire around 2029, allowing for potential market entry. Cipla anticipates capturing a significant share of this lucrative market segment after the launch. Additionally, the company reported a 35% decline in consolidated net profit in the September quarter.

    Cipla Q2 net profit falls 35% to Rs 878 crore, revenue dips 2%

    Cipla reported a 35% year-on-year decline in second-quarter net profit to Rs 878 crore, with revenue and EBITDA also falling amid weaker North American sales. India revenue grew 12%, while US regulatory approval and a biosimilar partnership supported its product pipeline.

    Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%

    Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-year decline in revenue from operations, totaling Rs 7,404 crore. Additionally, a significant 26.7% decrease in EBITDA resulted in a lower margin of 18.7%. Nonetheless, Cipla's One India division demonstrated growth across various segments, while the company aims to enhance productivity and innovate its product offerings.

    Nifty 50 companies likely to log strong double-digit growth in Q2

    Revenue and net profit of Nifty 50 companies are projected to grow by nearly 20% year-on-year. Analysts note that performance is driven by sectors like automobiles, banking, and oil. Operating margins, however, might contract slightly due to input cost pressures and inflation. Key sectors show varied conditions, balancing strong demand against potential challenges. Overall, medium to long-term outlook remains optimistic, despite some near-term volatility.

    Cipla global CEO Umang Vohra to step down; Achin Gupta to take over

    Cipla's global CEO Umang Vohra will step down in March 2026. Achin Gupta, currently global COO, will take over as the new MD and GCEO from April 1, 2026. Gupta joined Cipla in 2021 and has been instrumental in driving growth and strengthening operations. He holds degrees from IIT Delhi and IIM Ahmedabad.

    Reports of likely promoter stake sale making people anxious: Cipla MD Vohra

    "We're all human beings, we get distracted with what happens, because of this and that distraction creates difficulties for us in the way we engage with each other, and the way we engage with the organization. That, I believe, is the biggest impact of this uncertainty," Vohra added. Vohra said the promoters' and the company are two different entities.

    The Economic Times
    BACK TO TOP